Oliver Luxxe Assets LLC Buys Shares of 156,488 Amneal Pharmaceuticals, Inc. $AMRX

Oliver Luxxe Assets LLC bought a new position in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) in the 4th quarter, Holdings Channel reports. The firm bought 156,488 shares of the company’s stock, valued at approximately $1,972,000.

A number of other hedge funds and other institutional investors have also made changes to their positions in the company. Tudor Investment Corp ET AL bought a new stake in shares of Amneal Pharmaceuticals in the third quarter valued at about $921,000. Mirabella Financial Services LLP bought a new position in Amneal Pharmaceuticals during the 3rd quarter worth about $147,000. CIBC Bancorp USA Inc. bought a new position in Amneal Pharmaceuticals during the 3rd quarter worth about $161,000. Danske Bank A S purchased a new position in Amneal Pharmaceuticals during the 3rd quarter valued at about $1,092,000. Finally, Advisory Services Network LLC purchased a new position in Amneal Pharmaceuticals during the 3rd quarter valued at about $50,000. Institutional investors own 31.82% of the company’s stock.

Amneal Pharmaceuticals Stock Performance

Shares of Amneal Pharmaceuticals stock opened at $11.83 on Friday. The company has a market capitalization of $3.72 billion, a PE ratio of 51.44 and a beta of 1.35. The company has a 50-day simple moving average of $13.70 and a two-hundred day simple moving average of $12.09. Amneal Pharmaceuticals, Inc. has a one year low of $6.68 and a one year high of $15.42.

Analyst Ratings Changes

Several equities research analysts have recently weighed in on the stock. Barclays initiated coverage on shares of Amneal Pharmaceuticals in a research report on Monday, December 8th. They issued an “overweight” rating and a $15.00 price target for the company. Truist Financial lifted their price objective on shares of Amneal Pharmaceuticals from $15.00 to $17.00 and gave the company a “buy” rating in a report on Monday, March 2nd. Weiss Ratings reissued a “hold (c)” rating on shares of Amneal Pharmaceuticals in a research note on Wednesday, January 21st. Finally, Zacks Research upgraded Amneal Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a report on Friday, March 6th. One research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has given a Hold rating to the company’s stock. According to data from MarketBeat.com, Amneal Pharmaceuticals currently has an average rating of “Buy” and a consensus target price of $14.20.

Amneal Pharmaceuticals Profile

Amneal Pharmaceuticals, Inc is a publicly traded integrated healthcare company specializing in the development, manufacturing and distribution of generic and specialty pharmaceutical products. The company’s portfolio includes oral solids, injectables, transdermals and biosimilars, serving a broad range of therapeutic areas such as cardiovascular, neuroscience, oncology and women’s health. Alongside its generic offerings, Amneal has built a branded portfolio through strategic acquisitions and internal development, positioning itself across both high-volume generics and higher-value specialty treatments.

Since its founding in 2002 by brothers Chirag and Chintu Modgil, Amneal has pursued growth through organic investment in research and development as well as targeted M&A.